Stockscreener 앱 받기
29.82
0.85%
0.36
전일 마감가:
$29.46
열려 있는:
$29.12
하루 거래량:
1.45M
Relative Volume:
0.36
시가총액:
$4.85B
수익:
$56.99M
순이익/손실:
$-107.23M
주가수익비율:
-36.37
EPS:
-0.8199
순현금흐름:
$-142.55M
1주 성능:
-8.75%
1개월 성능:
+46.93%
6개월 성능:
+207.24%
1년 성능:
+421.23%
1일 변동 폭
$29.01
$30.31
1주일 범위
$28.60
$33.53
52주 변동 폭
$5.34
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
29.77 | 5.09B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
526.52 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
650.47 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.91 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
314.95 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.01 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Canaccord Genuity | Buy |
| 2026-02-23 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
TNGX Q1 2026 Earnings: Net Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances PipelineHigh Growth Earnings - dars.gov.et
TNGX Maintained by Canaccord Genuity -- Price Target Raised to $46 - GuruFocus
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark - marketscreener.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000E Growth Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
TNGX Upgraded by Jefferies -- Price Target Raised to $60 - GuruFocus
Tango Therapeutics Inc (TNGX) Institutional Confidence - TradingKey
Tango Therapeutics, Inc. Actuals & Estimates (NASDAQ:TNGX) - TradingView
Enterprise value to EBIT forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data By Investing.com - Investing.com Nigeria
Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60 - Moomoo
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data - Investing.com
TNGX Forecast — Price Target — Prediction for 2027 - TradingView
Why is Tango Therapeutics stock surging today? By Investing.com - Investing.com Nigeria
Price to sales forward of Tango Therapeutics, Inc. – NASDAQ:TNGX - TradingView
Form 8K Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 4 Tango Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
Director at Tango Therapeutics (TNGX) receives RSUs and stock options - Stock Titan
New Tango Therapeutics (TNGX) director Robert Azelby files initial Form 3 - Stock Titan
Robert Azelby appointed to Tango Therapeutics board, joins Compensation and NCG Committees - TradingView
Biotech veteran Robert Azelby joins Tango Therapeutics (TNGX) board as company advances vopimetostat - Stock Titan
Positive trial data lifts forecasts for Tango Therapeutics’ oncology program - S&P Global
Tango Therapeutics Appoints New Board Member - Intellectia AI
Tango Therapeutics Company Profile & Introduction - Moomoo
Tango Therapeutics appoints Robert Azelby to board of directors By Investing.com - Investing.com South Africa
Tango Therapeutics appoints Robert Azelby to board of directors - Investing.com
Tango Therapeutics Appoints Robert Azelby to Board of Directors - The Manila Times
Press Release: Tango Therapeutics Appoints Robert Azelby to Board of Directors - Moomoo
Tango Therapeutics files for $500 million common stock offering - MSN
ACUTA CAPITAL PARTNERS, LLC's Tango Therapeutics Inc(TNGX) Holding History - GuruFocus
Tango Therapeutics Inc (TNGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tango Therapeutics stock hits all-time high at 33.19 USD By Investing.com - Investing.com Australia
TNGX (Nasdaq: TNGX) affiliate files Form 144 to sell 3.5M shares - Stock Titan
Tango Therapeutics stock hits all-time high at 33.19 USD - Investing.com
Tango Therapeutics Inc (TNGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tango Therapeutics Inc 주식 (TNGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
Jul 01 '26 |
Sale |
29.59 |
27,000 |
798,908 |
115,743 |
0.56%
0.50%
자본화:
|
볼륨(24시간):